There is a need to identify patients who may benefit from particular treatments. We investigated prognosis in 915 patients with mCRC from 2 phase III trials of panitumumab plus chemotherapy, based on Köhne category and BRAF status. Both Köhne category and BRAF status predicted outcomes in terms of PFS and OS, and panitumumab provided benefits over chemotherapy alone. Background: Köhne prognostic score is used to classify patients with metastatic colorectal cancer (mCRC) as high, intermediate, or low risk. Using data from 2 phase III trials, we analyzed survival in patients categorized according to Köhne prognostic category and virus-induced rapidly accelerated fibrosarcoma murine sarcoma viral oncogene homolog B (BRAF) mutation. Patients and Methods: PRIME (Panitumumab Randomized Trial In Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy) (first-line) and 20050181 (second-line) were studies of chemotherapy with or without panitumumab. Progression-free survival (PFS) and overall survival (OS) were analyzed retrospectively in rat sarcoma viral oncogene homolog (RAS) wild type (WT) and RAS WTþBRAF WT mCRC in each Köhne category, and in BRAF mutant (MT) mCRC. Results: In PRIME (n ¼ 495) and 20050181 (n ¼ 420), 53 (11%) and 44 (10%) patients, respectively, had BRAF MT mCRC. Of the RAS WTþBRAF WT/unknown populations, 85/267/90 and 82/211/83 were categorized as high/medium/low risk, respectively. PFS and OS hazard ratios (HRs), adjusted for Köhne group, for patients with RAS WT þ BRAF WT/unknown mCRC favored panitumumab with chemotherapy versus chemotherapy alone in both studies. In PRIME, the PFS HR was 0.74 (95% confidence interval [CI], 0.61-0.90) and OS HR was 0.78 (95% CI, 0.64-0.95). In 20050181, PFS and OS HRs were 0.80 (95% CI, 0.65-0.99) and 0.78 (95% CI, 0.62-0.99), respectively. Median PFS and OS were lower in patients with BRAF MT mCRC than in any of the 3 risk categories for patients with RAS WTþBRAF WT/unknown mCRC. Conclusion: During firstand second-line treatment, Köhne prognostic score allows accurate risk classification in RAS WT mCRC. BRAF MT mCRC should be classified as high risk regardless of other parameters. Panitumumab with chemotherapy might provide survival benefits versus chemotherapy alone in RAS WT and RAS WTþBRAF WT/unknown mCRC, overall and across risk categories.
Introduction
Survival outcomes in patients with metastatic colorectal cancer (mCRC) differ widely depending on their disease characteristics at the start of treatment. Furthermore, the choice of first-and second-line treatment is generally made on the basis of patient and disease characteristics, treatment goal (eg, resection or disease control), and rat sarcoma viral oncogene homolog (RAS) status. 1 Thus there is a need to define patient subgroups who will derive the most benefit from specific treatments. An analysis of data from 3825 patients with mCRC showed that they can be divided into 3 prognostic categories (high, medium, and low risk) on the basis of 4 baseline clinical parameters 2 : Eastern Cooperative Oncology Group (ECOG) performance status, white blood cell count, alkaline phosphatase levels, and number of metastatic sites. The importance of these parameters has been confirmed in studies of regimens including oxaliplatin and irinotecan combinations. 3, 4 More recently, mutations in the virus-induced rapidly accelerated fibrosarcoma murine sarcoma viral oncogene homolog B (BRAF) gene have also been identified as a negative prognostic marker in mCRC. [5] [6] [7] [8] [9] Epidermal growth factor receptor (EGFR) inhibitors are an important treatment option for patients with mCRC. 1, 10 These agents are licensed only for patients whose tumors have wild type (WT) RAS genes (KRAS and NRAS ), because RAS mutations result in a lack of response to EGFR inhibitors. [11] [12] [13] [14] [15] Several phase III trials have shown the efficacy and tolerability of the EGFR inhibitor panitumumab in patients with RAS WT mCRC. 16 For example, results from the first-line PRIME (Panitumumab Randomized Trial In Combination With Chemotherapy for Metastatic Colorectal
Cancer to Determine Efficacy) study showed that panitumumab significantly improved overall survival (OS) when combined with leucovorin, 5-fluorouracil, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone. 8 In the second-line 20050181 study, panitumumab with leucovorin, 5-fluorouracil, and irinotecan (FOL-FIRI) significantly improved progression-free survival (PFS) versus FOLFIRI alone in patients with RAS WT mCRC. 17 Using data from the PRIME and 20050181 studies, we retrospectively analyzed survival outcomes in patients with mCRC categorized according to Köhne prognostic category and BRAF mutation status.
Patients and Methods

Study Design
The PRIME (ClinicalTrials.gov: NCT00364013) and 20050181 (NCT00339183) were international, open-label phase III studies in which patients were randomized (1:1) to receive FOLFOX4 (PRIME) or FOLFIRI (20050181) with or without panitumumab. Full details of these studies have been published previously. 18, 19 In brief, eligible patients were adults with metastatic adenocarcinoma of the colon or rectum, and an ECOG performance status of 0 to 2. In PRIME, patients were previously untreated, whereas those in 20050181 had previously progressed while receiving, or within 6 months of, 1 previous fluoropyrimidine-based mCRC therapy. In both studies, panitumumab was administered as an intravenous infusion of 6.0 mg/kg on the first day of each 14- studies, KRAS exon 2 testing was performed in a blinded central laboratory using allele-specific polymerase chain reaction (DxS Ltd, Manchester, United Kingdom). 18, 19 RAS mutations beyond KRAS exon 2 were detected using bidirectional Sanger sequencing (both studies) and using WAVE-based Surveyor Scan Kits (Transgenomic Inc, Omaha, NB; PRIME only) in WT KRAS exon 2 tumor specimens. 8, 17 Patients were characterized as having RAS mutations if any predefined activating mutation in KRAS or NRAS was detected.
Patients were also categorized on the basis of BRAF mutation status (exon 15 [V600E]), assessed using bidirectional Sanger sequencing in WT KRAS exon 2 tumor specimens (both studies) and using WAVEbased SURVEYOR Scan Kits (Transgenomic Inc; PRIME only).
8,17
Survival Analysis
Progression-free survival and OS were analyzed retrospectively for the overall RAS WT population for each Köhne prognostic category, established on the basis of data from before the previous first-line therapy was started. In a second analysis, patients with BRAF mutant (MT) mCRC were analyzed separately, with the remaining patients then analyzed according to Köhne prognostic category (see Supplemental Figure 1 in the online version). For the purposes of this analysis, patients from PRIME with unknown BRAF status were grouped together with patients who had BRAF WT tumors, although a separate analysis was conducted in which patients with unknown BRAF status were excluded.
For PRIME, the analysis was conducted when 80% of patients enrolled in the study had died. For 20050181, the primary analysis data cutoff (380 PFS events) was used. Survival was analyzed using the KaplaneMeier method and presented as median (95% confidence interval [CI] ) values. Hazard ratios (HRs) for PFS and OS in the panitumumab with FOLFOX4 arm versus the FOLFOX4-alone arm, and the panitumumab with FOLFIRI arm versus the FOLFIRIalone arm, were calculated using a Cox proportional hazards model. All of the analyses were exploratory and descriptive in nature. 
Survival in RAS WT mCRC According to Köhne Category and BRAF Status
Results
Patients
Of 1183 patients enrolled in PRIME, 505 (43%) had RAS WT mCRC, of whom 494 (98%) had sufficient data for a Köhne prognostic category to be established, with 97, 297, and 100 patients categorized as high, medium, and low risk, respectively. Of 1186 patients enrolled in the 20050181 study, 421 had RAS WT mCRC, of whom 419 (>99%) had sufficient data for a Köhne prognostic category to be established, with 92 high-risk, 235 medium-risk, and 92 low-risk patients.
Of the 505 patients in PRIME with RAS WT mCRC, tumors from 53 patients (11%) were categorized as BRAF MT (see Supplemental Figure 2 in the online version). BRAF status was unknown in 13 patients (3%); these were grouped alongside patients with BRAF WT status for the purposes of the analysis. The remaining RAS WTþBRAF WT/unknown analysis included 85, 267, and 90 patients categorized as high, medium, and low risk, respectively. In the 20050181 study, BRAF status was known for all patients, and tumors from 44 (10%) of the 421 patients with RAS WT mCRC were categorized as BRAF MT, including 1 patient who 
Overall RAS WT Analysis
For PRIME, data were fully mature for OS analysis (median follow-up, 80 weeks), with 80 (94%), 212 (81%), and 65 (75%) patients in the high, medium, and low risk categories, respectively, having died at the time of analysis. At the time of analysis in the 20050181 study (median follow-up, 48 weeks), the number of deaths was 73 (79%), 147 (63%), and 51 (55%), respectively.
In the RAS WT population, the PFS and OS HRs adjusted for Köhne prognostic group favored panitumumab with chemotherapy versus chemotherapy alone in both studies (Table 1 ). In PRIME, the PFS HR was 0.74 (95% CI, 0.62-0.90) and the OS HR was 0.76 (95% CI, 0.63-0.93). In the 20050181 study, the PFS and OS HRs were 0.78 (95% CI, 0.63-0.96) and 0.82 (95% CI, 0.64-1.04), respectively.
Outcome in Patients With RAS WTþBRAF WT/ Unknown mCRC
As in the RAS WT population, the PFS and OS HRs adjusted for Köhne prognostic group for patients with RAS WTþBRAF WT/ unknown mCRC favored panitumumab with chemotherapy versus chemotherapy alone in both studies (Table 2 ; Figures 1 and 2 ; see Supplemental Figures 3-6 in the online version). In PRIME, the (Table 2) . Results were similar when the 13 patients with unknown BRAF status were excluded from the PRIME analysis (see Supplemental Table 2 in the online version).
Survival in RAS
WT mCRC According to Köhne Category and BRAF Status PFS HR was 0.74 (95% CI, 0.62-0.90) and the OS HR was 0.78 (95% CI, 0.64-0.95), whereas in the 20050181 study the PFS
Discussion
The results of our analysis of PRIME study data confirm that, in patients with previously untreated mCRC, the prognostic scoring system developed by Köhne and colleagues 2 allows accurate risk classification in RAS WT and RAS WT þBRAF WT/unknown mCRC. On the basis of data from the 20050181 study, we have shown for the first time that the Köhne score also allows risk classification in patients with RAS WT mCRC undergoing second-line treatment. In both studies, Köhne categorization was particularly successful for prediction of OS.
As previously reported, 5-9 the presence of BRAF mutations was a strong negative prognostic marker for outcome in both studies, and such patients should be classified as high risk regardless of other clinical parameters. Notably, the prevalence of BRAF mutations varies between studies. In the triplet plus bevacizumab (TRIBE) study, for example, 6% of patients had BRAF mutations, 20 compared with 11% and 12%, respectively, in the present analyses of the PRIME and 20050181 studies. In contrast, 21% of tumors in a Scandinavian registry had BRAF mutations. 21 It should also be noted that only 1 specific BRAF mutation (V600E) was evaluated in our study, and it is possible that other BRAF mutations would have different effects on outcomes.
22,23
The overall efficacy results of the PRIME and 20050181 studies showed that PFS was improved by the additional use of panitumumab with chemotherapy. 8, 17 OS was also improved by the additional use of panitumumab with FOLFOX4 in the PRIME study. 12 In the 20050181 study, OS was numerically longer with panitumumab with FOLFIRI than with FOLFIRI alone. 24 Consistent with this, the HRs in these retrospective, exploratory analyses suggest that panitumumab with chemotherapy might provide PFS and OS benefits versus chemotherapy alone in patients with RAS WT and RAS WTþBRAF WT/unknown mCRC, overall and across Köhne risk categories. Furthermore, a pilot study of firstline panitumumab monotherapy has shown the activity and tolerability of treatment in frail elderly patients with gastrointestinal cancer classified as Köhne intermediate or high risk. 25 The treatment guidelines issued by the European Society of Medical Oncology in 2016 recommend that the aim of treatment should be considered in management decisions for patients with mCRC. 1 The guidelines broadly define 2 patient categories: those with potentially resectable disease or who need a rapid reduction in tumor symptoms, for whom cytoreduction is the primary aim of treatment, and those for whom the aim is disease control and aggressive treatment is not necessary. The results of our analysis suggest that panitumumab improves outcomes for both of these patient subgroups: aggressive Köhne high-risk mCRC and nonaggressive Köhne low-risk mCRC.
One of the strengths of the present work is that it is on the basis of data from phase III, randomized, controlled trials, although these were retrospective, post hoc analyses, and thus only descriptive data are reported. The present work was also limited by the small patient numbers in some subgroups. Further analysis using other prognostic scores, such as the Groupe Coopérateur Multidisciplinaire en Oncologie model 26 or the neutrophil/lymphocyte ratio, 27 might be of interest. More recently, side of disease of the primary tumor (left vs. right colon) has emerged as a predictive and prognostic variable, 28-31 which might be driven by BRAF and other unfavorable mutations. Indeed, the percentage of patients with right-sided disease in the present analysis was higher in the BRAF MT group than in any of the 3 Köhne prognostic groups, which each had a similar percentage of patients with right-sided disease. As a result of the small number of patients with right-sided disease in the present study, however, we did not conduct any further analysis of the prognostic effect of primary tumor location. In the era of molecular subtyping-for example using mutational profile, 32 gene expression, 33 or protein levels-it will be interesting to correlate clinical subgroups to the underlying molecular alterations. Finally, it has been suggested that the prognostic ability of the Köhne model could be improved by incorporating baseline serum lactate dehydrogenase levels and quality of life measures of pain and mobility. 34 
Conclusion
In patients with untreated mCRC, Köhne prognostic score allows accurate risk classification in RAS WT and RAS WTþBRAF WT/ unknown mCRC, particularly with regard to OS. Thus, Köhne score can be used as a stratification factor in future clinical trials even when targeted agents are used. Although the Köhne prognostic score was developed for use in the first-line mCRC setting, we show for the first time that it also allows risk classification in patients with RAS WT and RAS WT/BRAF WT mCRC undergoing second-line treatment. BRAF mutations are also strongly negatively prognostic for outcome, and patients with BRAF MT mCRC should be classified as high risk regardless of other clinical parameters. The HRs in this retrospective, exploratory analysis suggest that panitumumab with chemotherapy might provide PFS and OS benefits versus chemotherapy alone in patients with RAS WT and RAS WTþBRAF WT/unknown mCRC, overall and across risk categories. Further research is necessary to investigate the relationship between Köhne prognostic category and other known risk factors, such as primary tumor location.
Clinical Practice Points
Survival outcomes in patients with metastatic colorectal cancer (mCRC) differ widely depending on their disease characteristics at the start of treatment. Choice of treatment is generally made on the basis of patient and disease characteristics, treatment goal (e.g., resection or disease control), and RAS status. Patients with mCRC can be divided into 3 Köhne prognostic categories (high, medium and low risk) based on 4 baseline clinical parameters. Mutations in the BRAF gene have been identified as a negative prognostic marker in mCRC. Several phase III trials have demonstrated the efficacy and tolerability of the EGFR inhibitor panitumumab in patients with RAS WT mCRC.
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In patients with previously untreated mCRC, Köhne prognostic scoring allows accurate risk classification in RAS WT and RAS WTþBRAF WT/unknown mCRC. The Köhne score also allows risk classification in patients with RAS WT mCRC undergoing second-line treatment. Köhne categorisation was particularly successful for prediction of OS. The presence of BRAF mutations was a strong negative prognostic marker for outcome in both studies. Köhne score can be used as a stratification factor in future clinical trials even when targeted agents are used.
Patients with BRAF MT mCRC should be classified as high risk regardless of other clinical parameters. Panitumumab with chemotherapy may provide PFS and OS benefits versus chemotherapy alone in patients with RAS WT and RAS WTþBRAF WT/unknown mCRC, overall and across risk categories. 48  44  40  36  32  28  24  20  16  12  8  4  0   5  7  9  12  14  24  37  41  6  8  10  14  17  21  36  46 
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